Sego Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Sego Pharma
Largest movements
- Current investments +€136,151
up €136,151 (+79.8%), from €170,535 to €306,686
- Cash +€52,945
up €52,945 (+62.7%), from €84,479 to €137,424
mainly Net result for the year (+€153,475) and Other debts (+€97,195)
- Receivables within one year -€28,265
down €28,265 (-12.2%), from €231,001 to €202,737
of which Other amounts receivable: -€20,918
- Tangible fixed assets -€27,643
down €27,643 (-29.1%), from €95,067 to €67,424
- Profit (loss) carried forward +€153,475
up €153,475 (+36.2%), from €424,099 to €577,574
- Reserves -€120,525
down €120,525 (-98.5%), from €122,385 to €1,860
- Other debts +€97,195
up €97,195 (+416.6%), from €23,330 to €120,525
- Debts after one year -€12,389
down €12,389 (-36.4%), from €34,069 to €21,680
- Current portion of long-term debt +€11,756
up €11,756 (+67.2%), from €17,488 to €29,244
- Staff costs -€12,710
down €12,710 (-7.3%), from €173,205 to €160,495
- Gross operating margin +€10,629
up €10,629 (+2.7%), from €386,790 to €397,420
- Taxes +€8,409
up €8,409 (+19.5%), from €43,098 to €51,507
- Depreciation -€5,282
down €5,282 (-16.0%), from €32,926 to €27,643
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €806,833 | €939,072 | +€132,239 | +16.4% |
| Fixed assets | 21/28 | €97,567 | €69,924 | -€27,643 | -28.3% |
| Tangible fixed assets | 22/27 | €95,067 | €67,424 | -€27,643 | -29.1% |
| Land and buildings | 22 | €64,148 | €52,120 | -€12,028 | -18.7% |
| Plant, machinery and equipment | 23 | €21,043 | €9,719 | -€11,324 | -53.8% |
| Furniture and vehicles | 24 | €9,876 | €5,585 | -€4,291 | -43.5% |
| Financial fixed assets | 28 | €2,500 | €2,500 | = | 0.0% |
| Current assets | 29/58 | €709,266 | €869,149 | +€159,882 | +22.5% |
| Stocks and contracts in progress | 3 | €207,504 | €200,493 | -€7,011 | -3.4% |
| Stocks | 30/36 | €207,504 | €200,493 | -€7,011 | -3.4% |
| Amounts receivable within one year | 40/41 | €231,001 | €202,737 | -€28,265 | -12.2% |
| Trade receivables | 40 | €182,292 | €174,945 | -€7,347 | -4.0% |
| Other amounts receivable | 41 | €48,710 | €27,792 | -€20,918 | -42.9% |
| Current investments | 50/53 | €170,535 | €306,686 | +€136,151 | +79.8% |
| Cash at bank and in hand | 54/58 | €84,479 | €137,424 | +€52,945 | +62.7% |
| Deferred charges and accrued income | 490/1 | €15,747 | €21,809 | +€6,062 | +38.5% |
| Total equity and liabilities | 10/49 | €806,833 | €939,072 | +€132,239 | +16.4% |
| Equity | 10/15 | €565,085 | €598,034 | +€32,950 | +5.8% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €122,385 | €1,860 | -€120,525 | -98.5% |
| Distributable reserves | 133 | €122,385 | €1,860 | -€120,525 | -98.5% |
| Profit (loss) carried forward | 14 | €424,099 | €577,574 | +€153,475 | +36.2% |
| Amounts payable | 17/49 | €241,749 | €341,038 | +€99,289 | +41.1% |
| Amounts payable after more than one year | 17 | €34,069 | €21,680 | -€12,389 | -36.4% |
| Financial debts | 170/4 | €34,069 | €21,680 | -€12,389 | -36.4% |
| Amounts payable within one year | 42/48 | €207,602 | €318,861 | +€111,259 | +53.6% |
| Current portion of amounts payable after more than one year | 42 | €17,488 | €29,244 | +€11,756 | +67.2% |
| Trade debts | 44 | €143,765 | €145,513 | +€1,748 | +1.2% |
| Suppliers | 440/4 | €143,765 | €145,513 | +€1,748 | +1.2% |
| Taxes, remuneration and social security | 45 | €23,018 | €23,578 | +€560 | +2.4% |
| Taxes | 450/3 | €4,062 | €5,185 | +€1,123 | +27.7% |
| Remuneration and social security | 454/9 | €18,957 | €18,393 | -€564 | -3.0% |
| Other amounts payable | 47/48 | €23,330 | €120,525 | +€97,195 | +416.6% |
| Accrued charges and deferred income | 492/3 | €78 | €497 | +€419 | +534.0% |
| Remuneration, social security and pensions | 62 | €173,205 | €160,495 | -€12,710 | -7.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €32,926 | €27,643 | -€5,282 | -16.0% |
| Other operating charges | 640/8 | €1,005 | €1,042 | +€37 | +3.7% |
| Gross operating margin | 9900 | €386,790 | €397,420 | +€10,629 | +2.7% |
| Operating profit (loss) | 9901 | €179,654 | €208,239 | +€28,585 | +15.9% |
| Financial income | 75/76B | €4,754 | €4,688 | -€65 | -1.4% |
| Recurring financial income | 75 | €4,754 | €4,688 | -€65 | -1.4% |
| Financial charges | 65/66B | €10,680 | €7,944 | -€2,736 | -25.6% |
| Recurring financial charges | 65 | €10,680 | €7,944 | -€2,736 | -25.6% |
| Profit (loss) for the period before taxes | 9903 | €173,728 | €204,983 | +€31,255 | +18.0% |
| Income taxes | 67/77 | €43,098 | €51,507 | +€8,409 | +19.5% |
| Profit (loss) for the period | 9904 | €130,629 | €153,475 | +€22,846 | +17.5% |
| Profit (loss) for the period to be appropriated | 9905 | €130,629 | €153,475 | +€22,846 | +17.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 12 October 2026 via checked.be.